InterVenn Investigator Initiated Research Program in Glycoproteomics
June 10, 2021

InterVenn Biosciences Announces Clinical Validation of World’s First Glycoproteomic Diagnostic Test

— Business Wire, Inc.
Read the complete article here
April 15, 2021

InterVenn Biosciences Announces that Padmanee Sharma, MD, PhD, has Joined the Company’s Board of Advisors

— Odessa American
Read the complete article here
April 15, 2021

InterVenn Biosciences Announces that Nobel Laureate James P. Allison, PhD, has Joined the Company’s Board of Advisors

— BioSpace
Read the complete article here
April 12, 2021

InterVenn’s Glycoproteomic-based Biomarker Signature Successfully Predicts Favorable Outcomes in Metastatic Malignant Melanoma Patients Treated with Checkpoint Inhibitors

— Business Wire, Inc.
Read the complete article here
March 15, 2021

Glycoproteomics: A powerful new biomarker domain debuts in translational research

— SelectScience
Read the complete article here
January 7, 2021

$34M Funding Helps Speed Up New Class of Cancer Diagnostics

— Ovarian Cancer News Today
Read the complete article here
December 21, 2020

Follow the Money: Decentralized Trials, Stem Cell Research, Stroke Treatment

— Clinical Research News
Read the complete article here
December 11, 2020

Filipino-run biotech company develops ovarian cancer detection tool

— Manila Bulletin
Read the complete article here
December 7, 2020

P2 Billion Raised: This Filipino CEO's Biotech Startup is Working On Early Detection of Ovarian Cancer

— Esquire
Read the complete article here
December 2, 2020

Fighting ovarian cancer

— Daily Guardian
Read the complete article here
November 17, 2020

With a ‘monopoly’ on glycoproteomics, InterVenn raises $34M to push cancer diagnostic into the clinic, woos Illumina BD exec

— San Diego Biotechnology Network
Read the complete article here
November 17, 2020

With a 'Monopoly' on Glycoproteomics, InterVenn Raises $34M to Push Cancer Diagnostic Into the clinic, Woos Illumina BD Exec

— Endpoints News.
Read the complete article here
November 16, 2020

InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer

— Yahoo! Finance
Read the complete article here
November 16, 2020

Intervenn Biosciences Raises $34M To Commercialize Glycoproteomic Ldt For Ovarian Cancer And Immuno-oncology; Taps John Leite, Ph.d., As Chief Business Officer | Business Wire

— Trusted Insight
Read the complete article here
November 16, 2020

InterVenn Biosciences Raises $34M to Commercialize Glycoproteomic LDT for Ovarian Cancer and Immuno-oncology; taps John Leite, Ph.D., as Chief Business Officer

— Yahoo! News
Read the complete article here
November 16, 2020

"InterVenn Biosciences Raises $34M in Series B Round to Commercialize Ovarian Cancer Tests"

— Genomeweb.
Read the complete article here
November 16, 2020

"InterVenn Biosciences Raises $34M For Ovarian Cancer, Immuno-oncology Therapies"

— Crunchbase.
Read the complete article here
November 16, 2020

"InterVenn Biosciences raises $34 million to accelerate cancer test development with AI"

— Venture Beat.
Read the complete article here
November 10, 2020

"InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics"

— Businesswire.
Read the complete article here
November 10, 2020

"InterVenn Biosciences Reports Results on Vista™ : a Multi-Indication Liquid Biopsy Research Panel Built on Glycoproteomics"

— Businesswire.
Read the complete article here
October 20, 2020

"Agilent, InterVenn to Partner on Clinical Glycoproteomic Analysis"

— Genomeweb.
Read the complete article here
October 19, 2020

"INTERVENN - AGILENT TECHNOLOGIES COLLABORATION ON CLINICAL GLYCOPROTEOMIC ANALYSIS"

— Bernama.
Read the complete article here
October 13, 2020

"Intervenn Biosciences IDs COVID-19 risk biomarkers using glycoproteomics"

— BioWorld.
Read the complete article here
October 13, 2020

"InterVenn Biosciences Uses Glycoproteomics to Identify Potential COVID-19 Susceptibility Markers"

— Yahoo Finance.
Read the complete article here
June 22, 2020

"This Week’s AI & Drug Discovery Conference Xcelerating Life Sciences San Francisco Features insitro, Atomwise, twoXAR, InterVenn, Engine Biosciences & More"

— Xconomy, Inc.
Read the complete article here
March 25, 2020

"InterVenn Developing Glycoproteomic Assay for Colorectal Cancer Screening"

— GenomeWeb
Read the complete article here
March 23, 2020

"InterVenn Biosciences Adds Glycoproteomic Clinical Testing Panel for Colorectal Cancer and Advanced Adenoma"

— Business Wire, Inc.
Read the complete article here
February 5, 2020

"InterVenn Biosciences’ Blood Based Test Developed Using Artificial Intelligence Successfully Detects Nasopharyngeal Cancer"

— NAM News Network
Read the complete article here
February 5, 2020

"InterVenn innovates cancer diagnostics using AI"

— New Straits Times
Read the complete article here
February 2, 2020

"Meet the Silicon Valley-based Filipino founder fighting to end cancer"

— SparkUp, BusinessWorld Publishing
Read the complete article here
January 17, 2020

"InterVenn Biosciences Advances Glycoproteomics for Complex Disease Therapies"

— BioSpectrum
Read the complete article here
January 13, 2020

"InterVenn Biosciences Expands Work in Glycoproteomics to Successfully Target a Range of Cancers and Other Indications"

— BioSpace
Read the complete article here
January 13, 2020

"InterVenn Biosciences Advances Glycoproteomics to Propel Understanding and Find New Therapies in Complex Diseases"

— Business Wire, Inc.
Read the complete article here
December 17, 2019

"Malaysian breathrough in clinical study on ovarian cancer blood test"

— New Straits Times
Read the complete article here
December 4, 2019

"InterVenn Biosciences Releases First-Ever Software for AI-Enabled Mass Spec Analysis"

— Business Wire, Inc.
Read the complete article here
November 18, 2019

"InterVenn Biosciences Announces Positive Interim Clinical Trial Results and Appoints Biotech Veteran Klaus Lindpaintner, M.D. as Chief Scientific and Medical Officer"

— Business Wire, Inc.
Read the complete article here
June 3, 2019

"InterVenn BioSciences Enrolls First Patients in VOCAL Trial"

— BioSpace
Read the complete article here
December 14, 2018

"Top VC deals: Plaid raises at $2.65 billion; The Riveter reels in cash to build coworking spaces for women"

— CNBC LLC
Read the complete article here
December 12, 2018

"The Funded: Plaid's 10X valuation jump tops $450M in midweek deals"

— American City Business Journals
Read the complete article here
December 12, 2018

"InterVenn BioSciences Raises $9.4 Million to Help Physicians Detect Early Ovarian Cancer With a Minimally Invasive Test"

— Business Wire, Inc.
Read the complete article here
December 12, 2018

"InterVenn BioSciences Raises $9.4M in Funding"

— FinSMEs
Read the complete article here